Hushan Yang

Prof. Dr. Hushan Yang

Division of Population Science, Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2016 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
CWChun Wang
Chun Wang
ZMZhaomei Mu
Zhaomei Mu
ICInna Chervoneva
Inna Chervoneva
LALaura Austin
Laura Austin
ZYZhong Ye
Zhong Ye
HYHushan Yang
Hushan Yang

16 November 2015 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
ZMZhaomei Mu
Zhaomei Mu
CWChun Wang
Chun Wang
ZYZhong Ye
Zhong Ye
LALaura Austin
Laura Austin
JCJesse Civan
Jesse Civan
MCMassimo Cristofanilli
Massimo Cristofanilli

19 July 2017 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
QWQ. Wei
Q. Wei
ZYZ. Ye
Z. Ye
XZX. Zhong
X. Zhong
LLL. Li
L. Li
CWC. Wang
C. Wang
HYHushan Yang
Hushan Yang
Distant metastasis accounts for 90% of deaths from colorectal cancer (CRC). Genomic heterogeneity has been reported in various solid malignancies, but remains largely under-explored in metastatic CRC tumors, especially in primary to metastatic tumor evolution. We conducted high-depth whole-exome sequencing in multiple regions of matched primary and metastatic CRC tumors. Using a total of 28 tumor, normal, and lymph node tissues, we analyzed inter- and intra-individual heterogeneity, inferred the tumor subclonal architectures, and depicted the subclonal evolutionary routes from primary to metastatic tumors. CRC has significant inter-individual but relatively limited intra-individual heterogeneity. Genomic landscapes were more similar within primary, metastatic, or lymph node tumors than across these types. Metastatic tumors exhibited less intratumor heterogeneity than primary tumors, indicating that single-region sequencing may be adequate to identify important metastasis mutations to guide treatment. Remarkably, all metastatic tumors inherited multiple genetically distinct subclones from primary tumors, supporting a possible polyclonal seeding mechanism for metastasis. Analysis of one patient with the trio samples of primary, metastatic, and lymph node tumors supported a mechanism of synchronous parallel dissemination from the primary to metastatic tumors that was not mediated through lymph nodes. In CRC, metastatic tumors have different but less heterogeneous genomic landscapes than primary tumors. It is possible that CRC metastasis is, at least partly, mediated through a polyclonal seeding mechanism. These findings demonstrated the rationale and feasibility for identifying and targeting primary tumor-derived metastasis-potent subclones for the prediction, prevention, and treatment of CRC metastasis.

1 May 2016 in Gastroenterology
Verified
Journal Article
Open access
PDF file
YLYinzhi Lai
Yinzhi Lai
CWChun Wang
Chun Wang
JCJesse M. Civan
Jesse M. Civan
JPJuan P. Palazzo
Juan P. Palazzo
ZYZhong Ye
Zhong Ye
HYHushan Yang
Hushan Yang
As the second leading cause of cancer death in the United States, colorectal cancer (CRC), including colon and rectal cancers, disproportionally has affected black men and women for more than 20 years.1 x 1 Irby, K., Anderson, W.F., Henson, D.E. et al. Emerging and widening colorectal carcinoma disparities between blacks and whites in the United States (1975-2002). Cancer Epidemiol Biomarkers Prev. 2006; 15: 792–797 Crossref | PubMed | Scopus (90) | Google Scholar See all References , 2 x 2 Grubbs, S.S., Polite, B.N., Carney, J. et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol. 2013; 31: 1928–1930 Crossref | PubMed | Scopus (62) | Google Scholar See all References , 3 x 3 Robbins, A.S., Siegel, R.L., and Jemal, A. Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol. 2012; 30: 401–405 Crossref | PubMed | Scopus (101) | Google Scholar See all References Black patients have a higher CRC incidence, often are diagnosed at more advanced stages, and have worse overall outcomes than white patients.3 x 3 Robbins, A.S., Siegel, R.L., and Jemal, A. Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol. 2012; 30: 401–405 Crossref | PubMed | Scopus (101) | Google Scholar See all References , 4 x 4 Simpson, D.R., Martínez, M.E., Gupta, S. et al. Racial disparity in consultation, treatment, and the impact on survival in metastatic colorectal cancer. J Natl Cancer Inst. 2013; 105: 1814–1820 Crossref | PubMed | Scopus (29) | Google Scholar See all References , 5 x 5 Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review 1975-2012. National Cancer Institute. Bethesda, MD. Available at http://seer.cancer.gov/csr/1975_2012/. Accessed April 2015. Google Scholar See all References Although some biological differences have been proposed to exist between black and white CRC patients,6 x 6 Alexander, D., Chatla, C., Funkhouser, E. et al. Postsurgical disparity in survival between African Americans and Caucasians with colonic adenocarcinoma. Cancer. 2004; 101: 66–76 Crossref | PubMed | Scopus (41) | Google Scholar See all References it has been shown that socioeconomic and sociodemographic status may be the major driving factors for disparities in both CRC incidence and outcomes.7 x 7 Laiyemo, A.O., Doubeni, C., Pinsky, P.F. et al. Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst. 2010; 102: 538–546 Crossref | PubMed | Scopus (115) | Google Scholar See all References , 8 x 8 Du, X.L., Fang, S., Vernon, S.W. et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007; 110: 660–669 Crossref | PubMed | Scopus (124) | Google Scholar See all References , 9 x 9 Du, X.L., Meyer, T.E., and Franzini, L. Meta-analysis of racial disparities in survival in association with socioeconomic status among men and women with colon cancer. Cancer. 2007; 109: 2161–2170 Crossref | PubMed | Scopus (78) | Google Scholar See all References , 10 x 10 Rodgers, G.M. 3rd, Becker, P.S., Bennett, C.L. et al. Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008; 6: 536–564 Crossref | PubMed | Google Scholar See all References For instance, sociodemographic status can affect many risk and protective factors for CRC such as lifestyle factors (diet and exercise) and health care utilization (screening, diagnosis, and treatment).11 x 11 Ward, E., Jemal, A., Cokkinides, V. et al. Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin. 2004; 54: 78–93 Crossref | PubMed | Scopus (948) | Google Scholar See all References , 12 x 12 Lemmens, V.E., van Halteren, A.H., Janssen-Heijnen, M.L. et al. Adjuvant treatment for elderly patients with stage III colon cancer in the southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol. 2005; 16: 767–772 Crossref | PubMed | Scopus (102) | Google Scholar See all References It is important to identify those factors relating to socioeconomic and sociodemographic status that can be modified, to facilitate the design and implementation of appropriate policies and interventions to minimize racial disparities in CRC patients.

11 April 2016 in Scientific Reports
Verified
Journal Article
Open access
LLLing Li
Ling Li
HHHie-Won Hann
Hie-Won Hann
SWShaogui Wan
Shaogui Wan
RHRichard S. Hann
Richard S. Hann
CWChun Wang
Chun Wang
HYHushan Yang
Hushan Yang
Recent studies have demonstrated a potential link between circulating cell-free mitochondrial DNA (mtDNA) content and cancers. However, there is no study evaluating the association between circulating mtDNA as a non-invasive marker of hepatocellular carcinoma (HCC) risk. We conducted a nested case-control study to determine circulating mtDNA content in serum samples from 116 HBV-related HCC cases and 232 frequency-matched cancer-free HBV controls, and evaluate the retrospective association between mtDNA content and HCC risk using logistic regression and their temporal relationship using a mixed effects model. HCC cases had significantly lower circulating mtDNA content than controls (1.06 versus 2.47,P = 1.7 × 10−5). Compared to HBV patients with higher mtDNA content, those with lower mtDNA content had a significantly increased risk of HCC with an odds ratio (OR) of 2.19 (95% confidence interval [CI] 1.28–3.72,P = 0.004). Quartile analyses revealed a significant dose-dependent effect (Ptrend = 0.001) for this association. In a pilot longitudinal sub-cohort of 14 matched cases-control pairs, we observed a trend of dramatically decreased mtDNA content in cases and slightly decreased mtDNA content in controls, with a significant interaction of case-control status with time (Pinteraction = 0.049). Our findings suggest that circulating mtDNA is a potential novel non-invasive biomarker of HCC risk in HBV patients.

1 January 2012 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
JXJinliang Xing
Jinliang Xing
SWShaogui Wan
Shaogui Wan
FZFeng Zhou
Feng Zhou
FQFalin Qu
Falin Qu
BLBingshan Li
Bingshan Li
HYHushan Yang
Hushan Yang
Background: Cumulative data have shown that microRNAs (miRNA) are involved in the etiology and prognosis of colorectal cancer (CRC). Genetic polymorphisms in pre-miRNA genes may influence the biogenesis and functions of their host miRNAs. However, whether these polymorphisms are associated with CRC prognosis remains unknown. Methods: We analyzed the effects of seven single-nucleotide polymorphisms (SNP) in pre-miRNA genes on the prognosis of a Chinese population with 408 CRC patients with surgically-resected adenocarcinoma. Results: Two SNPs were identified to be significantly associated with recurrence-free survival and overall survival of the patients. The most significant SNP was rs6505162 in pre-miR-423. Compared with the homozygous wild-type genotype, the variant-containing genotypes of this SNP were significantly associated with both the overall survival (HR = 2.12, 95% CI = 1.34–3.34, P = 0.001) and the recurrence-free survival (HR = 1.59, 95% CI = 1.08–2.36, P = 0.019). Another SNP, rs4919510 in pre-miR-608, was also associated with altered recurrence-free survival (HR = 0.61, 95% CI = 0.41–0.92, P = 0.017). These effects were evident only in patients receiving chemotherapy but not in those without chemotherapy. In addition, the combined analysis of the two SNPs conferred a 2.84-fold (95% CI = 1.50–5.37, P = 0.001) increased risk of recurrence and/or death. Similarly, this effect was only prominent in those receiving chemotherapy (P < 0.001) but not in those without chemotherapy (P = 0.999). Conclusions: Our data suggest that genetic polymorphisms in pre-miRNA genes may impact CRC prognosis especially in patients receiving chemotherapy, a finding that warrants further independent validation. Impact: This is one of the first studies showing a prognostic role of pre-miRNA gene SNPs in CRC. Cancer Epidemiol Biomarkers Prev; 21(1); 217–27. ©2011 AACR.